EUVIMEDEUVIMED entdecken
Crossref

First Report of Antibiotic Resistance Markers cfi A and nim Among Bacteroides fragilis Group Strains in Ecuadorian Patients

Gabriela Sevillano, Ariane Paz Y Miño, María Belén Solís, Juan Pablo Vaca, Camilo Zurita-Salinas, Jeannete Zurita

Microbial Drug Resistance · 2023-11 · 29 (11) · 533-539

DOI: 10.1089/mdr.2023.0125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Drug Resistance, online erschienen am 07.11.2023. Verfasst von Gabriela Sevillano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito, Ecuador. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteroides Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, increasing resistance of Bacteroides fragilis to several antibiotics has been reported in different countries. The aim of this study was to evaluate the antibiotic resistance profiles of Bacteroides spp. isolated from clinical samples by phenotypic and molecular methods. A total of 40 nonrepetitive isolates of the B. fragilis group were studied from 2018 to 2019. The species was identified by API 20A system. The minimum inhibitory concentrations (MICs) were determined by Sensititre anaerobe MIC plate. The presence of the nim and cfiA genes was checked by conventional PCR. The association between genes and insertion sequence (IS) was performed by whole genome sequencing. Eleven isolates were categorized as metronidazole-resistant and only 2 isolates harbored the nim gene. Five isolates were imipenem-resistant, but cfiA gene was detected in two isolates. cfi A gene was closely related to the cfi A-4 allele and associated with IS614B. The nim gene was not related to any nim gene type and was considered a new variant named nim L. IS612 was found upstream of nim L gene. In view of the scarcity of data on B. fragilis , there is a need to surveil antibiotic resistance levels and molecular mechanisms to implement better antimicrobial therapies against this important group of bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteroides InfectionsHumansBacteroidesBacteroides fragilisEcuadorbeta-LactamasesMicrobial Sensitivity TestsDrug Resistance, BacterialBacterial Proteins

Stichwörter der Autor:innen

anaerobesimipenem resistanceinsertion sequencemetronidazole resistanceresistance mechanisms

Substanzen

Anti-Bacterial Agentsbeta-LactamasesBacterial Proteins

Autor:innen und Institutionen

  • Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito, Ecuador.
  • Carrera de Ingeniería en Biotecnología, Departamento de Ciencias de la Vida, Universidad de las Fuerzas Armadas-ESPE, Sangolquí, Ecuador.
  • Cátedra de Inmunología, Carrera de Medicina, Universidad Central del Ecuador, Quito, Ecuador.
  • Pontificia Universidad Católica del Ecuador, Quito, Ecuador.

Zitieren

APA

Sevillano, G., Paz Y Miño, A., Solís, M. B., Vaca, J. P., Zurita-Salinas, C., & Zurita, J. (2023). First Report of Antibiotic Resistance Markers cfi A and nim Among Bacteroides fragilis Group Strains in Ecuadorian Patients. Microbial Drug Resistance, 29(11), 533-539. https://doi.org/10.1089/mdr.2023.0125

Vancouver

Sevillano G, Paz Y Miño A, Solís MB, Vaca JP, Zurita-Salinas C, Zurita J. First Report of Antibiotic Resistance Markers cfi A and nim Among Bacteroides fragilis Group Strains in Ecuadorian Patients. Microbial Drug Resistance. 2023;29(11):533-539. doi:10.1089/mdr.2023.0125

BibTeX
@article{Sevillano2023,
  author = {Sevillano, Gabriela and Paz Y Miño, Ariane and Solís, María Belén and Vaca, Juan Pablo and Zurita-Salinas, Camilo and Zurita, Jeannete},
  title = {First Report of Antibiotic Resistance Markers cfi A and nim Among Bacteroides fragilis Group Strains in Ecuadorian Patients},
  journal = {Microbial Drug Resistance},
  year = {2023},
  volume = {29},
  number = {11},
  pages = {533--539},
  doi = {10.1089/mdr.2023.0125}
}
Kostenlos starten →